Neuronetics (Neuronetics) Debt-to-Asset : 0.54 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Neuronetics Debt-to-Asset?

Neuronetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.85 Mil. Neuronetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $61.63 Mil. Neuronetics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $115.83 Mil. Neuronetics's debt to asset for the quarter that ended in Dec. 2023 was 0.54.

Neuronetics Debt-to-Asset Historical Data

The historical data trend for Neuronetics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Debt-to-Asset Chart

Neuronetics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.34

0.49

0.28

0.34

0.54

Neuronetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.34	0.39	0.40	0.43	0.54

Competitive Comparison of Neuronetics's Debt-to-Asset

For the Diagnostics & Research subindustry, Neuronetics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuronetics's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Neuronetics's Debt-to-Asset falls into.

Neuronetics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Neuronetics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.845	+	61.629)	/	115.831
	=	0.54

Neuronetics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.845	+	61.629)	/	115.831
	=	0.54

Neuronetics (NAS:STIM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Neuronetics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Neuronetics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuronetics (Neuronetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (NAS:STIM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

NRC:Germany

Address

3222 Phoenixville Pike, Malvern, PA, USA, 19355

Website

https://www.neurostar.com

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Executives

Keith J Sullivan	director, officer: President and CEO	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
William Andrew Macan	officer: Sr. VP, GC, CCO and Secretary	24275 KATY FREEWAY, SUITE 600, KATY TX 77494
Stephen Furlong	officer: CFO	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Robert Cascella	director	C/O HOLOGIC, INC., BEDFORD MA 01730
John K Bakewell	director	C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NO. BILLERICA MA 01862
Cannell Capital Llc	10 percent owner	245 MERIWETHER CIRCLE, ALTA WY 83414
Joseph H Capper	director	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Bruce Joseph Shook	director	162 CRICKET AVE, ARDMORE PA 19003
Megan Rosengarten	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Sheryl L Conley	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Wilfred E Jaeger	director	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Glenn P Muir	director	C/O HOLOGIC, INC., BEDFORD MA 01730
Gregory Harper	officer: VP of Prod. Dev. & Operations	C/O NEURONETICS, INC, 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Brian E Farley	director	2200 ZANKER ROAD, SUITE F, SAN JOSE CA 95131
Daniel Guthrie	officer: Chief Commercial Officer	C/O NEURONETICS, INC, 322 PHOENIXVILLE PIKE, MALVERN PA 19355